First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03665155|
Recruitment Status : Recruiting
First Posted : September 11, 2018
Last Update Posted : January 17, 2019
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: 89Zr-daratumumab Device: PET/CT scans Other: Blood draws||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||This is a phase I/II study with the goal to assess the feasibility of using the anti-CD38 monoclonal antibody daratumumab, labeled with Zirconium-89 (89Zr ) through deferoxamine (DFO), known as 89Zr-DFO-daratumumab, for PET imaging of multiple myeloma.|
|Masking:||None (Open Label)|
|Official Title:||First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody|
|Actual Study Start Date :||September 5, 2018|
|Estimated Primary Completion Date :||September 2021|
|Estimated Study Completion Date :||September 2021|
Three patients will be administered 2 mCi of 89Zr-daratumumab in a total of 50 mg of daratumumab antibody. Administered activity (1 to 5 mCi) of radioactivity and total amount of administered antibody (3 to 50 mg) will be adjusted in subsequent patients in order to maximize image quality.
Patients in phase I will have up to 4 PET/CT scans, multiple blood draws, whole-body counts, and safety monitoring to determine pharmacokinetics, radiation dosimetry, and safety of 89Zr-DFO-daratumumab for PET/CT imaging. Phase II (total of 21-24 patients). After pharmacokinetics and radiation dosimetry are determined in phase I, additional patients will be enrolled in phase II.
2 mCi of 89Zr-daratumumab will be administered on day 0.
Device: PET/CT scans
PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.
Other: Blood draws
Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,
- Evaluation of tissue distribution of 89Zr-DFO-daratumumab [ Time Frame: 2 years ]Standardized uptake value (SUV) in various organs will be estimated from VOI analysis of clinical images and converted to activity-time curves. The areas under the activity-time curves will be derived by integration, converted to residence times, and used as input to the OLINDA/EXM dosimetry program to obtain absorbed dose estimates for normal tissues.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03665155
|Contact: Gary Ulaner, MD, PhDfirstname.lastname@example.org|
|Contact: Ola Landgren, MD||212-639-5126|
|United States, New York|
|Memorial Slaon-Kettering Cancer Center||Recruiting|
|New York, New York, United States, 10065|
|Contact: Gary Ulaner, MD, Ph.D. 212-639-3776|
|Contact: Ola Landgren, MD 212-639-5126|
|Principal Investigator: Gary Ulaner, MD, Ph.D.|
|Principal Investigator:||Gary Ulaner, MD, PhD||Memorial Sloan Kettering Cancer Center|